Norman G, Mason T, Dumville J, Bower P, Wilson P, Cullum N
BMJ Open. 2023; 12(12):e064345.
PMID: 36600433
PMC: 10580278.
DOI: 10.1136/bmjopen-2022-064345.
Parihar S, Kaur R, Singh S
J Family Med Prim Care. 2021; 10(7):2441-2449.
PMID: 34568118
PMC: 8415662.
DOI: 10.4103/jfmpc.jfmpc_2320_20.
Kreps S, Prasad S, Brownstein J, Hswen Y, Garibaldi B, Zhang B
JAMA Netw Open. 2020; 3(10):e2025594.
PMID: 33079199
PMC: 7576409.
DOI: 10.1001/jamanetworkopen.2020.25594.
Zhao X, Zhang H, Li D, Zhou J, Chen Y, Sun Y
PLoS One. 2020; 15(6):e0234869.
PMID: 32579578
PMC: 7314029.
DOI: 10.1371/journal.pone.0234869.
Rachaniotis N, Dasaklis T, Pappis C
J Syst Sci Syst Eng. 2020; 26(2):219-239.
PMID: 32288410
PMC: 7104597.
DOI: 10.1007/s11518-016-5327-z.
Modelling the population effectiveness of the national seasonal influenza vaccination programme in Scotland: The impact of targeting all individuals aged 65 years and over.
Corson S, Robertson C, Reynolds A, McMenamin J
Influenza Other Respir Viruses. 2018; 13(4):354-363.
PMID: 29908098
PMC: 6586176.
DOI: 10.1111/irv.12583.
School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program.
Basurto-Davila R, Meltzer M, Mills D, Beeler Asay G, Cho B, Graitcer S
Health Serv Res. 2017; 52 Suppl 2:2307-2330.
PMID: 29130266
PMC: 5682124.
DOI: 10.1111/1475-6773.12786.
Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
Morcl T, Hurst B, Bart Tarbet E
Vaccine. 2017; 35(35 Pt B):4569-4577.
PMID: 28716554
PMC: 5562532.
DOI: 10.1016/j.vaccine.2017.07.016.
Pandemic influenza 2009: Impact of vaccination coverage on critical illness in children, a Canada and France observational study.
Flechelles O, Brissaud O, Fowler R, Ducruet T, Jouvet P, The Pediatric Canadian Critical Care Trials Group H N Collaborative And Groupe Francophone de Reanimation Et Urgences Pediatriques
World J Clin Pediatr. 2016; 5(4):374-382.
PMID: 27872826
PMC: 5099590.
DOI: 10.5409/wjcp.v5.i4.374.
From discovery to licensure, the Adjuvant System story.
Garcon N, Di Pasquale A
Hum Vaccin Immunother. 2016; 13(1):19-33.
PMID: 27636098
PMC: 5287309.
DOI: 10.1080/21645515.2016.1225635.
Twin Peaks: A/H1N1 Pandemic Influenza Virus Infection and Vaccination in Norway, 2009-2010.
Van Effelterre T, Dos Santos G, Shinde V
PLoS One. 2016; 11(3):e0151575.
PMID: 27010830
PMC: 4807012.
DOI: 10.1371/journal.pone.0151575.
Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.
Remschmidt C, Rieck T, Bodeker B, Wichmann O
BMC Infect Dis. 2015; 15:137.
PMID: 25887460
PMC: 4371628.
DOI: 10.1186/s12879-015-0882-3.
Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
Vaughn D, Seifert H, Hepburn A, Dewe W, Li P, Drame M
Hum Vaccin Immunother. 2014; 10(10):2942-57.
PMID: 25483467
PMC: 5443104.
DOI: 10.4161/21645515.2014.972149.
Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.
Syrjanen R, Jokinen J, Ziegler T, Sundman J, Lahdenkari M, Julkunen I
PLoS One. 2014; 9(9):e108538.
PMID: 25265186
PMC: 4180439.
DOI: 10.1371/journal.pone.0108538.
Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany.
Prestel J, Volkers P, Mentzer D, Lehmann H, Hartung H, Keller-Stanislawski B
Pharmacoepidemiol Drug Saf. 2014; 23(11):1192-204.
PMID: 24817531
PMC: 4282476.
DOI: 10.1002/pds.3638.
Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands.
Wijnans L, Dieleman J, Voordouw B, Sturkenboom M
PLoS One. 2013; 8(4):e63156.
PMID: 23646191
PMC: 3640023.
DOI: 10.1371/journal.pone.0063156.
Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010.
Borse R, Shrestha S, Fiore A, Atkins C, Singleton J, Furlow C
Emerg Infect Dis. 2013; 19(3):439-48.
PMID: 23622679
PMC: 3647645.
DOI: 10.3201/eid1903.120394.
Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom.
Pebody R, Andrews N, Fleming D, McMenamin J, Cottrell S, Smyth B
Epidemiol Infect. 2012; 141(3):620-30.
PMID: 22691710
PMC: 9151880.
DOI: 10.1017/S0950268812001148.
Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans.
Wise M, Viray M, Sejvar J, Lewis P, Baughman A, Connor W
Am J Epidemiol. 2012; 175(11):1110-9.
PMID: 22582209
PMC: 3888111.
DOI: 10.1093/aje/kws196.
Pandemic 2009 H1N1 virus infection in children and adults: A cohort study at a single hospital throughout the epidemic.
Rhim J, Go E, Lee K, Youn Y, Kim M, Park S
Int Arch Med. 2012; 5(1):13.
PMID: 22443897
PMC: 3331808.
DOI: 10.1186/1755-7682-5-13.